Videos

Although the guidance has created some confusion around pharmacists’ responsibilities on the federal and state levels, Lanton said it will take time to find cohesive solutions.

Heidi D. Finnes, PharmD, BCOP, FHOPA, current president of Hematology/Oncology Pharmacy Association (HOPA), explains how HOPA can help prepare PGY2 pharmacy residents to obtain and maintain their BCOP certification.

In addition to expanding patient access to Paxlovid, the recent authorization of pharmacists to prescribe the drug marks a step toward provider status.

Xenia Tigno, PhD, and Reshma Jagsi, MD, DPhil, discuss how the pandemic impacted women’s careers in medical research and other medical fields.

The panel of pharmacists discuss the immunization tracker registry and emphasize utilizing this tool in preparation for the coming flu season.

Key opinion leaders discuss common narratives and concerns regarding a variety of vaccines and share successful strategies to overcome vaccine reluctance.

Michael Ganio, PharmD, MS, BCPS, FASHP, senior director of pharmacy practice and quality at ASHP, discussed the declaration of monkeypox as a public health emergency

Drs Haumschild, Moore, and Dent provide strategies to optimize current and forthcoming HR+/HER2– breast cancer therapies while preserving patients’ quality of life.

Experts share forthcoming treatment options in the treatment of HR+/HER2– breast cancer.

Exploring the significant role of electronic medical records (EMR) in toxicity management for patients with HR+/HER2– breast cancer.

There is nothing that hurts us more when a pharmacist stands up and is not passionate about the job that we do and the care that we provide.

Evolutionary vaccine technologies driven by the COVID-19 pandemic are explored in a discussion led by Dr Cohen.

Pharmacists highlight patient hesitations surrounding vaccinations and offer a multitude of approaches for alleviating these concerns.

Insights on unmet needs in HR-positive, HER2-negative treatment management and on how pharmacists can optimize treatment strategies and patient outcomes.

The panel highlights opportunities for inclusive populations within trials for HR+/HER2- breast cancer, as well as pharmacist-led initiatives in clinical trial settings.

The first thing is educating these folks, because it's hard for them to understand our challenges if they don’t understand what we do.

Get involved, attend their sessions, attend their conferences, understand what they’re saying, make sure that we’re, again, speaking with that one common voice.

You just need to tell your story and be genuine and be real, and it makes such a difference.

We have to have this one voice that we've been talking about, this one consistent message.

Whether it was the ability to vaccinate, whether it was the ability to test, whether it's now the ability to prescribe Paxlovid for patients, those are big progress moves for the profession of pharmacy.

Daniel Gagnon, VP of Global UPS Healthcare, discusses vaccine equity panel discussion at the UPS Impact Summit in Atlanta, which was held at the National Center for Civil and Human Rights.

The experts provide their closing thoughts and discuss unmet needs in the treatment of patients with MCL.

Drs Haumschild, Jain, and Wang evaluate MCL therapies under investigation and the impact on the future of MCL treatment.

Key opinion leaders evaluate treatment options for MCL while emphasizing payer considerations.

When we talk about access, that is a pharmacist.

Health Mart University also offers "basic technician training programs," to allow pharmacies to bring those new technicians on board, help them meet the PTCB examination standards, and really get that new technician ready to go.

The panel concludes with their thoughts on the future of the AML treatment landscape.

Drs McCoy and McCloskey discuss relapsed/refractory AML, including treatment goals and options.

Health Mart was able to deliver the targeted education they needed in a virtual manner to allow them to start in the uniting and to keep their immunization credentials.

We need to be able to build on that momentum, and at the same time, we need sustainable reimbursement models.